Login to Your Account

Aventis Commits At Least $62M To ImmunoGen In Cancer Deal

By Aaron Lorenzo

Friday, August 1, 2003
ImmunoGen Inc. received a commitment worth at least $62 million from Aventis SA, which in turn acquired a large share of ImmunoGen's pipeline as part of an agreement to jointly develop antibody-based cancer products. And the deal could get sweeter from there. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription